Orig3N Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Orig3N Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10984
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Orig3N Inc (Orig3N), a biotechnology company that focuses on the research, development and treatment of genetically inherited diseases. The company offers DNA test kits which include SUPERHERO for analyzing strength, intelligence and speed; FITNESS that provides reports and analysis on various aspects of fitness including exercise recovery, metabolism, muscle strength, endurance, joints and power performance; Beauty for assessment on key aspects of skin including hydration, aging, elasticity, UV sensitivity. It also provides Life Capsule, a blood cell repository for regenerative medicine development. The company uses its regenerative medicine technology to develop ORIG3N C3LL Cardiomyocytes for diagnosing and treating diseases. Orig3N is headquartered in Boston, Massachusetts, the US.

Orig3N Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Orig3N Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Orig3N Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Orig3N Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Orig3N Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Orig3N Inc, Medical Devices Deals, 2012 to YTD 2018 9
Orig3N Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Orig3N Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Orig3n Raises Funds through Initial Closing of Series B Financing 12
Orig3n Raises USD20 Million in Venture Financing 14
Orig3N Raises USD12.5 Million in Series A Financing 16
Orig3N Raises USD5 Million in Venture Financing 18
Orig3N Raises Funds through Venture Financing 19
Orig3N Raises USD3.1 Million in Venture Financing 20
Partnerships 22
Orig3n Enters into Research Agreement with Harvard University 22
ORIG3N Partners with Kangstem Biotech 23
Orig3N Enters into Agreement with Sharp Edge Labs 24
Orig3N Enters into Research Agreement with Sturge-Weber 25
Orig3N Inc – Key Competitors 26
Orig3N Inc – Key Employees 27
Orig3N Inc – Locations And Subsidiaries 28
Head Office 28
Recent Developments 29
Other Significant Developments 29
Jun 08, 2018: Orig3n Announces Osteoarthritis Cartilage Regeneration for First Cell Therapy Program 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
Orig3N Inc, Pharmaceuticals & Healthcare, Key Facts 2
Orig3N Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Orig3N Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Orig3N Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Orig3N Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Orig3N Inc, Medical Devices Deals, 2012 to YTD 2018 9
Orig3N Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Orig3n Raises Funds through Initial Closing of Series B Financing 12
Orig3n Raises USD20 Million in Venture Financing 14
Orig3N Raises USD12.5 Million in Series A Financing 16
Orig3N Raises USD5 Million in Venture Financing 18
Orig3N Raises Funds through Venture Financing 19
Orig3N Raises USD3.1 Million in Venture Financing 20
Orig3n Enters into Research Agreement with Harvard University 22
ORIG3N Partners with Kangstem Biotech 23
Orig3N Enters into Agreement with Sharp Edge Labs 24
Orig3N Enters into Research Agreement with Sturge-Weber 25
Orig3N Inc, Key Competitors 26
Orig3N Inc, Key Employees 27

List of Figures
Orig3N Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Orig3N Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Orig3N Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Orig3N Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Orig3N Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Orig3N Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Orig3N Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Orig3N Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Orig3N Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Orig3N Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Dubai Electricity and Water Authority:企業の戦略的SWOT分析
    Dubai Electricity and Water Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and maj …
  • Keyence Corp (6861):企業の財務・戦略的SWOT分析
    Keyence Corp (6861) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Brookfield Property REIT Inc (BPYU):企業の財務・戦略的SWOT分析
    Brookfield Property REIT Inc (BPYU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Fortinet Inc (FTNT):企業の財務・戦略的SWOT分析
    Fortinet Inc (FTNT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Daya Materials Bhd (DAYA):企業の財務・戦略的SWOT分析
    Summary Daya Materials Bhd (DMB) is a chemical company that offers polymer compound solutions. The company provides bulk chemicals, catalysts, additives, inert support materials and deodorizing agents. Its polymer compound products include semi conductive compounds, medium-voltage XLPE compounds, lo …
  • Virgin Active Limited
    Virgin Active Limited - Strategy, SWOT and Corporate Finance Report Summary Virgin Active Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Color Genomics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Color Genomics, Inc. (Color) provides physician ordered genetic testing service that helps to identify hereditary cancer risk. The company’s clinical grade test provides actionable results that enable consumers and their doctors to create personalized screening and healthcare plan. Color ana …
  • Fresenius Kabi AG:製薬・医療:M&Aディール及び事業提携情報
    Summary Fresenius Kabi AG (Fresenius Kabi), a wholly owned subsidiary of Fresenius SE & Co KGaA, develops, manufactures and markets pharmaceuticals products and medical devices. The company's product portfolio includes intravenously administered drugs, infusion therapy products, medical devices and …
  • Neurodyn Life Sciences Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Neurodyn Life Sciences Inc (Neurodyn Life Sciences), formerly Neurodyn Inc is a provider of validation and development of bioactives for neuroprotection and early treatment of neurological diseases. The company's products include neuroprotectant, memogain, progranulin, and nerve pain treatme …
  • Hybrigenics SA (ALHYG):製薬・医療:M&Aディール及び事業提携情報
    Summary Hybrigenics SA (Hybrigenics) is a biopharmaceutical company that develops new targets and therapies against proliferative and non-cancerous diseases. Its lead product candidate Inecalcitol, is a vitamin D receptor agonist being assessed for various cancer indications including prostate cance …
  • Croma Security Solutions Group plc (CSSG):企業の財務・戦略的SWOT分析
    Croma Security Solutions Group plc (CSSG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Marubeni Corp (8002):電力:M&Aディール及び事業提携情報
    Summary Marubeni Corp (Marubeni) is an integrated trading and investment business that operates through its domestic and overseas subsidiaries. It provides various products and commodities such as agri and marine products, chemicals, energy, metals and minerals, machinery, textiles, forest products …
  • Laboratorios Farmaceuticos Rovi SA (ROVI):企業の財務・戦略的SWOT分析
    Summary Laboratorios Farmaceuticos Rovi SA (Rovi) is a developer and manufacturer of prescription and hospital products. The company offers hospital products such as Iomeron and Iopamiro, Multihance, Y Prohance, Sonovue, contrast injection systems, Sodium Heparin and Siklos. Its diagnostic products …
  • Lake Shore Gold Corp.:企業のM&A・事業提携・投資動向
    Lake Shore Gold Corp. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Lake Shore Gold Corp. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • CeraPedics Inc:医療機器:M&Aディール及び事業提携情報
    Summary CeraPedics Inc (Cerapedics) is a medical device company that develops and commercializes novel osteobiologic products. The company’s products include i-factor putty, a biologic bone graft that uses a unique small peptide attachment factor to target specific integrins in osteogenic cells to i …
  • Euler Hermes SA:戦略・SWOT・企業財務分析
    Euler Hermes SA - Strategy, SWOT and Corporate Finance Report Summary Euler Hermes SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Okamoto Industries, Inc.:企業の戦略・SWOT・財務情報
    Okamoto Industries, Inc. - Strategy, SWOT and Corporate Finance Report Summary Okamoto Industries, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • China Ming Yang Wind Power Group Ltd-エネルギー分野:企業M&A・提携分析
    Summary China Ming Yang Wind Power Group Limited (Ming Yang) is a wind equipment company that designs, manufactures, sells and services wind turbines. It also provides services such as technical training, transportation of wind turbines, installation of wind turbines, debugging service of wind gener …
  • Protagonist Therapeutics Inc (PTGX):製薬・医療:M&Aディール及び事業提携情報
    Summary Protagonist Therapeutics Inc (Protagonist) is a clinical-stage biopharmaceutical company that discovers and develops orally stable peptides as targeted therapies. The company through its proprietary technology platform develops structurally novel oral or injectable peptides for protein-prote …
  • PAL Holdings, Inc.:企業の戦略・SWOT・財務情報
    PAL Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary PAL Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆